Management of rabies in humans

Alan C. Jackson*, Mary J. Warrell, Charles E. Rupprecht, Hildegund C.J. Ertl, Bernhard Dietzschold, Michael O'Reilly, Richard P. Leach, Zhen F. Fu, William H. Wunner, Thomas P Bleck, Henry Wilde

*Corresponding author for this work

Research output: Contribution to journalReview article

162 Scopus citations

Abstract

Rabies is a fatal disease in humans, and, to date, the only survivors of the disease have received rabies vaccine before the onset of illness. The approach to management of the rabies normally should be palliative. In unusual circumstances, a decision may be made to use an aggressive approach to therapy for patients who present at an early stage of clinical disease. No single therapeutic agent is likely to be effective, but a combination of specific therapies could be considered, including rabies vaccine, rabies immunoglobulin, monoclonal antibodies, ribavirin, interferon-α, and ketamine. Corticosteroids should not be used. As research advances, new agents may become available in the future for the treatment of human rabies.

Original languageEnglish (US)
Pages (from-to)60-63
Number of pages4
JournalClinical Infectious Diseases
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Management of rabies in humans'. Together they form a unique fingerprint.

Cite this